Rachael Sirianni is a Professor at UMass Chan Medical School, Department of Neurological Surgery. Her affiliations include the T.H. Chan School of Medicine and multiple programs at the Morningside Graduate School of Biomedical Sciences, such as Cancer Biology, Neuroscience, and Translational Science. She holds degrees from Arizona State University (BSE Bioengineering), Yale University (MS and PhD in Biomedical Engineering). Her research focuses on nanomedicine, drug delivery systems, and biomedical engineering , with an emphasis on targeting neurological disorders and cancers. Key areas include nanoparticle-based therapies for glioblastoma, ALS, and pediatric brain tumors, as well as hormonal therapies for cognitive decline. She explores mechanisms like intranasal, intrathecal, and intravenous delivery to enhance CNS drug distribution. Her work bridges preclinical models and clinical translation, including studies on HDAC inhibitors, retinoid activation, and targeted drug release. Collaborations span neurosurgery, oncology, and biomaterials engineering. She has contributed to clinical trials for ependymoma and developed novel nanoparticle platforms for CNS drug delivery.










